Affordable Access

Publisher Website

Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.

Authors
Type
Published Article
Journal
Journal of Clinical Oncology
0732-183X
Publisher
American Society of Clinical Oncology
Publication Date
Volume
26
Issue
7
Pages
1135–1141
Identifiers
DOI: 10.1200/JCO.2007.14.3685
PMID: 18309949
Source
Medline

Abstract

Although the primary end point of a 20% PFS rate was not achieved, 13% of the patients had PFS for >or= 6 months. Given the tolerability and survival data, evaluation of enzastaurin in combination with cytotoxic drugs is warranted in NSCLC.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F